ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0855

Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

Claudia Mendoza-Pinto1, Pamela Munguía-Realpozo2, Karla Godinez-Bolaños2, Mario García-Carrasco2, Ivet Etchegaray-Morales2 and Socorro Méndez-Martínez3, 1Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, 2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 3Instituto Mexicano del Seguro Social, Puebla, Mexico

Meeting: ACR Convergence 2021

Keywords: Atherosclerosis, Imaging, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: To date, the prevalence and prognosis of coronary artery disease (CAD) according to the coronary calcium score (CCS) and coronary artery calcification (CAC) using coronary computed tomography in patients with rheumatic diseases, including systemic lupus erythematosus (SLE), have been investigated in various studies, but with conflicting results. The latest American Heart Association and American College of Cardiology (AHA/ACC) guidelines for the primary prevention of atherosclerotic cardiovascular disease (CVD) permit the CAC score to be used in intermediate-risk patients, in whom additional individual risk-enhancing clinical factors such as chronic inflammatory disease, such as SLE are present, if the risk level is uncertain.

The aim of this systematic review and meta-analysis was to synthesize the evidence on this topic.

Methods: Relevant literature was identified and evaluated from inception until January 2021 through multiple search strategies on PubMed, Embase, Web of Science and Cochrane library. Cross-sectional or cohort (baseline data) studies reporting CAC prevalence and the extent of CAC identified by the CCS were included. Data extracted from eligible studies were used to calculate estimated effect sizes (ESs) and 95% confidence intervals (95%CI) and weighted mean differences (WMD) with 95% CI (PROSPERO registration number: CRD42021228710).

Results: The search retrieved 80 articles, of which 23 were eligible for inclusion. For the CAC prevalence, 10 studies were included (842 SLE patients and 910 controls) and the pooled prevalence of the random effect size was 28.7% (95%CI 25.7-31.9%) for SLE patients and 19.3% (95%CI 16.2-21.4%) in controls (RR 1.92, 95%CI 1.3 to 2.9; p< 0.0001) with substantial heterogeneity (I2= 74%, p < 0.0001) (Fig 1) and there was no significant increase in the WMD for CCS (MD= 0.32, 95%CI -5.55 to 6.20, p= 0.91 and I2= 50%, p= 0.06) compared with controls (Fig 2), using data from 7 studies. Limited evidence suggests that patients with SLE had more multivessel CAD. Greater organ damage was associated with a higher CCS. Glucocorticoid use was associated with both prevalence or progression in CAC. According to two studies, coronary computed tomographic angiography showed the calcified and non-calcified plaque burden were increased in SLE patients compared with controls.

Conclusion: In patients with SLE, asymptomatic CAD by CAC is more prevalent and shows more multivessel disease compared with controls without lupus. However, the extent of CAC was not increased in SLE patients.

Meta-analysis of the weighted mean differences (WMD) of coronary calcium score in patients with SLE compared to controls


Disclosures: C. Mendoza-Pinto, None; P. Munguía-Realpozo, None; K. Godinez-Bolaños, None; M. García-Carrasco, None; I. Etchegaray-Morales, None; S. Méndez-Martínez, None.

To cite this abstract in AMA style:

Mendoza-Pinto C, Munguía-Realpozo P, Godinez-Bolaños K, García-Carrasco M, Etchegaray-Morales I, Méndez-Martínez S. Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/asymptomatic-coronary-artery-disease-assessed-by-coronary-computed-tomography-in-patients-with-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/asymptomatic-coronary-artery-disease-assessed-by-coronary-computed-tomography-in-patients-with-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology